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In 2005, the Centers for Disease Control and Prevention 
(CDC) started a 3-year colorectal cancer screening dem-
onstration project and funded five programs to explore 
the feasibility of a colorectal cancer program for the 
underserved U.S. population. CDC is evaluating the five 
programs to estimate implementation cost, identify best 
practices, and determine the most cost-effective approach. 
The objectives are to calculate start-up costs and estimate 
funding requirements for widespread implementation of 
colorectal cancer screening programs.
Methods
An instrument was developed to collect data on resource 
use and related costs. Costs were estimated for start-up 
activities, including program management, database devel-
opment, creation of partnerships, public education and 
outreach, quality assurance and professional development, 
and patient support. Monetary value of in-kind contribu-
tions to start-up programs was also estimated.
Results
Start-up time ranged from 9 to 11 months for the five pro-
grams; costs ranged from $60,602 to $337,715. CDC fund-
ing and in-kind contributions were key resources for the 
program start-up activities. The budget category with the 
largest expenditure was labor, which on average accounted 
for 67% of start-up costs. The largest cost categories by 
activities were management (28%), database development 
(17%), administrative (17%), and quality assurance (12%). 
Other significant expenditures included public education 
and outreach (9%) and patient support (8%).
Conclusion
To our knowledge, no previous reports detail the costs 
to begin a colorectal cancer screening program for the 
underserved population. Start-up costs were significant, 
an important consideration in planning and budgeting. 
In-kind contributions were also critical in overall program 
funding. Start-up costs vary by the infrastructure avail-
able and the unique design of programs. These findings 
can inform development of organized colorectal cancer 
programs.
Introduction
Screening for colorectal cancer (CRC) reduces mortality 
and improves quality of life through earlier detection of 
precancerous polyps and thus more effective treatment of 
cancers (1). Less than one-half of the eligible population in 
the United States are up to date with recommended CRC 
screening tests, and the uninsured are among those least 
likely to participate in screening programs (2,3). Screening 
programs for the uninsured should help to increase the 
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, 
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only 
and does not imply endorsement by any of the groups named above.
 www.cdc.gov/pcd/issues/2008/apr/07_0202.htm • Centers for Disease Control and Prevention 
Florence K.L. Tangka, PhD, Sujha Subramanian, PhD, Bela Bapat, MS, Laura C. Seeff, MD, Amy DeGroff, 
MPH, James Gardner, MSPH, A. Blythe Ryerson, MPH, Marion Nadel, PhD, Janet Royalty, MS
VOLUME 5: NO. 2
APRIL 2008
proportion of this subpopulation who are screened and 
improve health outcomes. Costs associated with offering 
screening tests and performing subsequent diagnostic 
procedures need to be assessed in program planning. Such 
economic assessment is an increasingly important tool 
that allows policy makers to plan for optimal allocation of 
limited health care resources, identify the most efficient 
approach to implementing screening programs, and assess 
annual budget implications.
CRC screening has been shown to be cost-effective in 
numerous studies using decision analytic models to assess 
the benefits and the cost of screening (4). The models have 
produced conflicting results on which of the screening tests 
for early detection of cancer recommended by the American 
Cancer Society guidelines (5,6) is most cost-effective. 
However, the models have been consistent in determining 
that screening for CRC with any of the recommended tests 
is more cost-effective than the alternative of no screening 
(7,8). To date, no evaluation effort has included careful 
assessment of the cost of offering CRC screening through 
organized programs in the United States. Overall costs of 
such programs go well beyond the cost of the individual 
screening tests provided. They include expenditures to hire 
staff, establish contracts and partnerships with provid-
ers, develop databases and other mechanisms to maintain 
records and track patient outcomes, recruit patients, pro-
vide professional education, and establish medical advisory 
boards. Programs that provide screening services to under-
served populations can incur significant costs in outreach, 
patient education, and case management.
The Centers for Disease Control and Prevention (CDC) 
established the Colorectal Cancer Screening Demonstration 
Program (CRCSDP) in 2005 to explore the feasibility of 
establishing a CRC screening program for the underserved 
U.S. population. Data from the five program sites funded 
through this effort provide a unique opportunity to under-
stand the costs associated with offering screening through 
organized programs. Each program is described in detail 
elsewhere in this issue (9,10).
CDC is undertaking a detailed evaluation of CRCSDP to 
estimate the cost of implementation (start-up and mainte-
nance), describe implementation processes, assess patient 
outcomes, and determine the relative cost-effectiveness of 
screening modalities. We report here on the start-up costs 
of establishing CRC screening programs, which include all 
expenditures before delivery of the service. This informa-
tion is essential for the estimation of the funding required 
to plan and start a CRC screening program. Subsequent 
reports will include costs incurred during the service deliv-
ery phase of the program.
Methods
We developed an instrument to collect data on use of 
resources and costs related to the start-up of CRCSDP. The 
start-up period was defined as the time between the date of 
the funding award (August 31, 2005) and the start of deliv-
ery of the screening service in each program. We knew that 
the times required to complete start-up activities for each 
program might differ, which would lead to an inconsistent 
duration of the start-up period for programs. Nevertheless, 
we adopted this definition to ensure that start-up activities 
and their costs were fully captured at each program site. 
Well-established methods for collecting cost data for 
program evaluation, such as the “ingredient approach,” 
were considered in designing the questionnaire (11-14) (S. 
Subramanian, PhD, unpublished data, 2006). Costs were 
assigned to four budget categories: staff salaries, contract 
expenditure, purchases, and administrative expenditure 
(Figure 1), and activities were placed in these categories. 
Activity-based costs were derived by aggregating expen-
ditures for staff salaries and labor, contractual costs, and 
purchases for each activity. We also collected overhead or 
indirect costs, including expenditures for items such as 
telecommunications and rent associated with CRCSDP. The 
monetary value of in-kind contributions provided to the pro-
grams during the start-up period was also estimated.
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Figure 1. Approach to collection of cost data in study of start-up costs 
in five programs in Colorectal Cancer Screening Demonstration Program, 
2005–2006
The cost instrument was designed to ensure collection of 
accurate data despite variations among the five programs. 
The programs differed in structure, provider network, 
selection of the screening test, and size of the service deliv-
ery area, and all of these factors affected costs. One of the 
five programs is implemented statewide, two are restricted 
to large urban areas (one city each), and two others serve 
clients throughout one to three counties. Two programs 
provide colonoscopy as the primary screening test, and the 
other three provide guaiac-based fecal occult blood tests. 
The structure for service delivery was more decentralized 
in some programs than in others. Decentralized programs, 
for example, contracted with providers to perform recruit-
ment, screening, and patient follow-up activities, whereas 
centralized programs did not outsource these activities. 
Provider networks varied by site and included hospitals, 
specialty care centers, state health departments, and com-
munity health centers.
All data were collected in Microsoft Excel (Microsoft 
Corporation, Redmond, Washington). Program staff entered 
the data prospectively into the Excel work sheets to ensure 
accuracy of the information and avoid issues related to 
recall bias. For example, program staff maintained a log of 
the activities performed that was updated on a weekly or 
monthly basis. Programs were also provided with a user 
guide giving detailed definitions of each activity captured 
for the start-up period. This guide assisted with data report-
ing and helped to ensure consistent reporting among all 
programs so that meaningful comparisons could be made. 
Evaluators conducted a series of conference calls with each 
site to provide additional guidance for data collection.
We analyzed costs according to CRCSDP program activi-
ties during the start-up period. In estimating the true labor 
costs, we used the information collected on 1) the number 
of hours worked by staff per month on various activities, 
2) the proportion of salary paid through CRCSDP funds, 
3) data on the percentage of time staff members worked, 
and 4) staff salary. The staff salary information was 
requested as either a range or the actual base salary in 
addition to the fringe benefit rate. We used the average of 
the lower and upper bounds of the salary range when nec-
essary. When salary information was not provided, we used 
national average compensation for a specific job category 
from the Bureau of Labor Statistics (www.bls.gov) or the 
average salary from a similar job category provided by the 
programs. On the basis of this information, we computed 
the hourly rate for labor and the proportion of in-kind 
labor cost — labor hours expended but not covered by CDC 
funds. The labor costs were then aggregated for each activ-
ity in each program.
For contract expenditures, we aggregated the costs of 
consultants and funding to provider sites by program activ-
ity, such as technology support and development of media 
materials. Costs for materials, equipment, and supplies 
were also computed for each activity in each program. We 
aggregated the overhead costs related to the start-up peri-
od and confirmed the activity-based cost estimates for each 
CRCSDP-funded activity by comparing the CRCSDP funds 
expended by each program. If discrepancies were noted, 
we contacted the program to clarify the data provided and 
resolve inconsistencies.
Results
The start-up periods for the five programs ranged from 9 
to 11 months. Details on the start-up activities are provid-
ed in Table 1. CDC funding and in-kind contributions were 
key resources for the program start-up activities. Funding 
sources for costs incurred by each program during the 
start-up period are shown in Table 2. The mean total cost 
for programs was $171,139. The lowest cost was $60,602, 
and the highest cost was $337,715. 
On average, CDC funding was 42% of total cost and 
in-kind contribution was 50%. CDC funds ranged from 
13% to 63% of total start-up costs. Two programs also 
received funding from other sources, including the state 
Comprehensive Cancer Control program and the state 
CRC task force. After excluding these two programs, the 
CRCSDP funding from CDC averaged 46%. For two of 
the programs, CDC funding for CRCSDP activities was 
substantially more than in-kind contributions. In-kind 
contributions varied among the programs and constituted 
28% to 67% of total costs. They included donated labor time 
(e.g., physicians on the medical advisory board) and sup-
plies such as computers. Labor was a major component of 
in-kind donations.
Distribution of start-up costs among budget categories is 
shown in Figure 2. The category with the largest expendi-
ture was labor, which on average accounted for 67% (range, 
55%–78%) of the start-up cost. Only one program incurred 
expenditures related to consultants; these costs were 2% 
of the total cost among all programs. On average among 
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the five programs, administrative cost was 17% (range, 
6%–34%) of the total cost, and the cost for materials and 
supplies was 14% (range, 5%–27%). Materials and sup-
plies included items such as postage, forms, brochures, and 
medical supplies.
For all programs combined, the largest cost categories 
by activity were management (28%; range, 18%–34%); 
data collection and tracking, which were mainly for data-
base development (17%; range, 8%–35%); administrative 
costs (17%; range, 6%–34%); and quality assurance (12%; 
range, 10%–15%) (Figure 3). Other activities with signifi-
cant expenditures included public education and outreach 
(9%; range, 6%–13%) and patient support (8%; range, 
0%–19%).
Cost allocations among activities for each of the five 
programs are shown in Figure 4. This distribution varied 
among the programs. Database development was the larg-
est cost category for program 1 (35%), and administration/
overhead was the largest category for program 4 (34%). The 
largest category for the other three programs was program 
management (25%–34%).
Discussion
To our knowledge, no previous evaluation has provided 
details on the costs to begin a CRC screening program for 
the underserved population. The important contributions 
of this paper include 1) the imputation of market value 
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Figure 2. Distribution of start-up costs, by budget category, in study of five 
programs in Colorectal Cancer Screening Demonstration Program, 2005–
2006 
Figure 3. Percentage distribution of start-up costs, by activity, averaged 
across the five programs in the Colorectal Cancer Screening Demonstration 
Program, 2005–2006. Numbers do not add up to 00% due to rounding.
Figure 4. Distribution of start-up costs, by activity, in study of five programs 
in Colorectal Cancer Screening Demonstration Program, 2005–2006 
to in-kind contributions (voluntary and donated services 
and products), which can help other programs explicitly 
account for in-kind contributions in their budgets in cases 
when these resources might not be freely available; 2) the 
categorization of cost components (Table 1), which provides 
a useful guide about different sources of costs; and 3) the 
provision of steps involved in the valuation of labor. Our 
analysis shows that start-up costs can be significant and 
should be considered in planning and budgeting for future 
CRC screening programs.
One of the largest cost components was overall program 
management, which involved a wide range of activities. 
Necessary resources included expenditures to develop 
fiscal systems, recruit and train staff, establish policies 
and procedures, and negotiate contracts with providers. 
Another significant cost component was developing a data-
base system to monitor and track patient services. Labor 
required to perform these activities was the most signifi-
cant budget category; materials and supplies accounted for 
a much smaller proportion of the total cost. Most of these 
activities represent fixed costs and therefore will not vary 
in relation to the volume of screens performed.
In this CRC screening demonstration, in-kind contribu-
tions were critical in providing the resources required for 
the start-up program activities. Therefore, total cost of 
start-up activities should include the monetary value of 
these contributions, which are generally related to dona-
tion of labor hours. This in-kind labor was mainly provided 
by senior management staff members, who were vital for 
the overall success of the program, and by physicians and 
other key individuals who participated in the medical 
advisory board to ensure that the program was designed 
to include pertinent clinical care partners and that quality 
care was provided to program participants. In future plan-
ning for resource allocation for a similar program, these 
critical categories should not be overlooked.
Start-up costs varied substantially across the five pro-
grams in this screening demonstration. The infrastructure 
available before the start of this effort accounts for some 
of the difference. For example, programs that could easily 
manipulate existing data-collection tools did not have to 
incur large expenses to create new data systems. Therefore, 
we can expect programs that plan to build on a well-estab-
lished infrastructure to incur smaller start-up costs than 
programs with limited infrastructure. Other sources of 
variation could include the type of screening tests offered, 
the geographic area covered, the setting in which the pro-
gram was created (e.g., academic medical center vs state 
health department), and individual program contributions 
to administrative costs, which were a significant proportion 
of total costs. Although we provided a user’s guide to mini-
mize inconsistencies in reporting data, programs may have 
differed in the allocation of expenses to the various activ-
ity-based categories. Systematic quantitative assessment 
of these variations in start-up cost was not possible because 
of the small number of pilot sites available. Finally, we 
did not assess the cost incurred in the start-up period in 
relation to the effectiveness of the services provided by the 
programs. An evaluation of the cost-effectiveness of the 
programs is planned, and results based on intermediate 
outcomes (cost per screen performed and cost per polyp/
cancer detected) will be reported in future publications. 
However, such a study cannot be conducted in the start-up 
phase of a program when no screening has occurred.
The information provided in this assessment on the 
magnitude of cost related to specific start-up activities can 
serve as a guide to estimation of start-up costs for fund-
ing agencies and organizations implementing screening 
programs. The detailed list of start-up activities developed 
for this study can also assist program staff to develop 
budget estimates, and the real-world cost values reported 
in this analysis can serve as a benchmark for evaluation 
of these estimates. Thus, our work should provide essen-
tial information for the successful start of CRC screening 
programs. Furthermore, details on implementation costs 
are expected to provide in-depth assessment of the costs 
associated with recommended screening tests and realistic 
estimates of the cost of diagnosis and complications.
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Tables
Table 1. Activity-Based Categories in Study of Start-Up Costs in Five Programs in Colorectal Cancer Screening Demonstration 
Program, 2005–2006
Program Activity Description
Program management Defining specific measurable and realistic objectives, including goals of screening 
Recruiting, hiring, and training staff
Developing fiscal system
Collaborating with Centers for Disease Control and Prevention
Establishing and managing related contracts
Identifying and contracting with local physicians and clinics to deliver screening services
Developing administrative policies and procedures
Managing programmatic, administrative, and reporting issues
Traveling for program meetings
Establishing necessary administrative billing and reimbursement system
Public education and outreach Developing and planning public education and outreach activities 
Conducting outreach and in-reach activities
Conducting and facilitating related training
Collaborating with partners
Quality assurance and professional 
development
Convening medical advisory board 
Developing quality-control standards and mechanisms
Developing clinical policies and procedures
Developing or enhancing training to educate and train health care professionals
Partnership development and maintenance Developing and maintaining partnerships (e.g., Comprehensive Cancer Control, medical health care sys-
tems, businesses)
Data collection and tracking Developing and adapting data-collection and reporting system 
Establishing surveillance system to track clients with abnormal screening results or diagnosis of cancer and 
follow up with them 
Patient support Establishing patient support system to provide appropriate screening, diagnostic, and treatment services 
Planning and identifying funding sources to ensure treatment services for people with cancer diagnosis or 
medical complications
Other activities Designing plan for program evaluation, job orientation, and training for collection of data on cost
Administrative/overhead costs Indirect costs (e.g., rent, telecommunications, maintenance)
Table 2. Distribution of Start-Up Costs, by Funding Source, Study of Five Programs in Colorectal Cancer Screening 
Demonstration Program (CRCSDP), 2005–2006
Funding Source
Programs
Mean1 2 3 4 5
Total, $ 5,0 60,602 6,9 7,75 65,775 7,9
In-kind contributions,a % 6 58 7 67 28 50
CDC funding, %  2 6  57 2
Other,b % 2 0 0 0 5 8
 
All percentages are computed as percentage of the total cost. 
a Labor costs and nonlabor costs (e.g., telephone calls, bowel preparation kits, printing of data-collection forms). 
b Includes Comprehensive Cancer Control program and colorectal cancer task force funding.
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